Clinical trials
Phase 4 Dementia trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2003 | 4 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 23 |
| Enrolling by invitation | 3 |
| Terminated | 2 |
| Withdrawn | 2 |
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| VA Office of Research and Development | 4 |
| Mayo Clinic | 3 |
| Novartis | 3 |
| Ariel Gildengers, MD | 1 |
| Avanir Pharmaceuticals | 1 |
| Baylor Research Institute | 1 |
| Centre for Addiction and Mental Health | 1 |
| Duke University | 1 |
| Emory University | 1 |
| Intermountain Health Care, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dementia | 33 |
| Alzheimer Disease | 16 |
| Cognitive Dysfunction | 11 |
| Psychomotor Agitation | 4 |
| Frontotemporal Dementia | 3 |
| Parkinson Disease | 3 |
| Dementia, Vascular | 2 |
| Lethargy | 2 |
| Lewy Body Disease | 2 |
| Mental Disorders | 2 |
Trials
Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.